Clinical Trial Update: A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours [Phase 1]

View source ↗

Summary

Clinical trial update describes a Phase 1 dose-escalation study of [225Ac]-FPI-2068 in adults with advanced solid tumors, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Gastric Cancer
• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer
• Pancreatic Ductal Adenocarcinoma
• Renal Cell Carcinoma
• Solid Tumor

Drugs mentioned

• [225Ac]-FPI-2068

Snippet

Sponsor: AstraZeneca | Conditions: Advanced Solid Tumor, Metastatic Colorectal Carcinoma | Phase 1 | Status: RECRUITING